top of page
iStock-1165058710.jpg

CoRegen, Inc. Attended Goldman Sachs’ Healthcare Private Company Conference

October 19, 2026

On October 19, 2026, Suneet Varma, CoRegen, Inc.’s Chairman of the Board, and Sonja Nelson, Chief Financial Officer, attended Goldman Sachs’ Inaugural Healthcare Private Company Conference, held in New York City.

Suneet also joined a panel discussion focused on “Innovation Powering the Future of Genetic Medicines.” He shared his perspectives on advancing innovation in cell therapy, overcoming barriers in solid tumors, and shaping the next generation of cell therapies.

About CoRegen

CoRegen is pioneering a novel approach to cancer treatment by inhibiting the SRC-3 gene in Regulatory T (Treg) cells, a type of adoptive cell therapy (ACT), enabling the immune system to recognize and eliminate solid tumors.

Research from the O’Malley Lab at Baylor College of Medicine has shown that genetically modified Treg cells alter their behavior, allowing them to penetrate tumors, release cytokines, and recruit immune cells to eradicate tumors in preclinical models.

bottom of page